Aurobindo in-licenced chemotherapy induced neutropenia drug Ryzneuta gets USFDA nod, sends scrip soaring to 52-week high

India Business News: Aurobindo Pharma has received approval from the US Food & Drug Administration (USFDA) for its long-acting Granulocyte colony-stimulating factor (G-CSF

Related Keywords

China ,United States ,New Jersey ,Yifan ,Zhejiang ,Bombay ,Maharashtra ,India ,Hyderabad ,Andhra Pradesh ,Los Angeles ,California ,Chinese ,Ryzneuta Efbemalenograstim ,Simon Li ,Aurobindo Pharma ,John Glaspy ,Ashish Anvekar ,Acrotech Biopharma ,China National Medical Products Administration ,University Of California ,Yifan Pharmaceutical Co Ltd ,Aurobindo Pharma United States Inc ,Los Angeles School Of Medicine ,Bombay Stock Exchange ,Jonsson Comprehensive Cancer Center ,Us Food Drug Administration ,Drug Administration ,Induced Neutropenia ,Hyderabad Based Aurobindo Pharma ,National Medical Products Administration ,Hyderabad Based Aurobindo ,Los Angeles School ,Business News ,Usfda Nod ,Us Regulatory Nod ,Chemotherapy ,